Becton, Dickinson and Company (BDX) recently completed the acquisition of HandyLab, Inc, an Ann Arbor, Michigan-based company that develops and manufactures automation platforms and molecular diagnostic assays. The transaction costs Becton $275 million.

The acquisition enables Becton to develop and commercialize its BD GeneOhm molecular assays on the HandyLab Jaguar platform, the first fully integrated molecular diagnostic system. The HandyLab instrumentation technology is considered to be an industry leading molecular diagnostic automation platform.

With the acquisition, Becton plans to market its BD GeneOhm molecular assays as the new BD Max system. Becton is a global leader in the treatment of healthcare associated infections (HAI). With growing concerns over HAI, hospitals are expanding their screening and testing programs and require automation systems to support their evolving needs.

Becton addresses HAI issues by supporting hospitals with its BD GeneOhm molecular testing product line and the HandyLab acquisition enables the company to expand the product line. The acquisition will boost demand for Becton’s molecular diagnostic products that will eventually drive the company’s top-line.

Becton, Dickinson and Company develops, manufactures and markets medical devices, supplies, laboratory equipment and diagnostic products globally. The company is a world leader in safety needle products. Becton competes with players like Baxter International (BAX), Johnson & Johnson (JNJ) and Abbott Laboratories (ABT).

We believe that Becton’s sound business model and product line should weather the current economic turbulence, and is capable of withstanding competitive pressure.

Zacks Investment Research

1. (BDX) Becton-Dickinson and Company Set for Acquisition of HandyLabBecton-Dickinson and Company (BDX) is set to acquire HandyLab Inc., an Ann Arbor, Michigan-based company...
2. (BDX) Becton, Dickinson and Co. Receives FDA Approval on Blood Collection DeviceBecton, Dickinson and Co. (BDX) announced that it received Food and Drug Administration (FDA) approval...
3. (BDX) Becton, Dickinson and Company Receives $52 Million Government OrderBecton, Dickinson and Company (BDX) received an order from the Biomedical Advanced Research and Development...
4. (BDX) Becton, Dickinson and Company – Growth And Income – Zacks Rank BuyBecton, Dickinson and Company (BDX) keeps seeing bullish forecasts on strong fundamentals as the company...
5. (BDX) Becton, Dickinson and Company – offers an industry-leading yield of 2%Becton, Dickinson and Company (BDX) recently declared a quarterly dividend of 33 cents per share,...
6. (BDX) Becton, Dickinson and Company – return on equity (ROE) of 23%, exceeding the industry average of 17%Becton, Dickinson and Company (BDX) offers a return on equity of 23%, exceeding the industry...

Search Posts by Tag: Abbott Laboratories | ABT | BAX | Baxter International Inc | BDX | Becton Dickinson Company | JNJ | Johnson & Johnson | Healthcare

RSS Feeds by Tag: Abbott Laboratories | ABT | BAX | Baxter International Inc | BDX | Becton Dickinson Company | JNJ | Johnson & Johnson | Healthcare |

Other Posts by: vitalstocks | RSS Feed for this author